Experiences from both shores of the Charles River, MA
BIH Lecture Series | Frontiers in Translational Medicine – Scientific and Structural Challenges
The successful translation of innovative technologies into new enterprises requires factors that are both internal and external to the entrepreneurial team. The Wyss Institute for Biologically Inspired Engineering at Harvard University has developed a unique model that draws the most innovative ideas from blue-sky research in leading academic groups throughout the Boston area, and then de-risks these technologies to create impactful product opportunities with the guidance of industry experts both inside and outside the walls of the Institute. The thoughtful assembly of a diverse team of many fully engaged stakeholders is equally important as the product development process in bringing a technology forward into the hands of patients or other end-users.
Combining entrepreneurial experience with her leadership responsibilities at the Wyss Institute, Dr. Fretzen will elaborate on the Wyss’ model and explore what she sees as the keys to the successful translation of technologies that have the ambitious goal of measurable positive impact on society.
Dr. Angelika Fretzen is a product development executive with over 20 years of experience in academia and biotech.
After training as organic chemist and earning a diploma from the Julius Maximilians Universität in Würzburg followed by a doctoral degree from the Université de Genève in Switzerland, Dr. Fretzen completed a postdoctoral fellowship with Gregory L. Verdine at Harvard University, where she witnessed the take-off and trajectory of the biotech sector in one of the leading innovation hubs in the world. Dr. Fretzen took the opportunity to join a team of young entrepreneurs at Ironwood Pharmaceuticals where she became Vice President of Chemical & Pharmaceutical Development, key inventor and member of the R&D team that successfully launched Linzess, for the treatment of gastrointestinal diseases. She then joined Catabasis as Senior Vice President of Pharmaceutical Development, overseeing the progression of edasalonexent from discovery to Phase 3 clinical development for the treatment of Duchenne Muscular Dystrophy. In 2019, Dr. Fretzen became part of the Executive Leadership Team at the Wyss Institute, assuming product and business development responsibilities, and she is currently transitioning into the role of the Institute’s Chief Operating Officer.
Due to the current situation regarding the BIH Lecture will be held Online via GoToMeeting. To participate in the BIH Lecture, please register in advance. The registration will be open until maximal participant capacity is reached.
Login via GoToMeeting
Please note that the login link and access code are not sent out immediately after your registration! You will receive both the evening before the event. You have the following possibilities to participate:
- You can download the GoToMeeting App beforehand (please do so before the lecture starts!)
- You can link in via the Browser (preferably Chrome)
- You can dial in by telephone (you will receive the dial-in number after your registration)
For security reasons, please login to GoToMeeting with your full name and institution (preferably in abbreviated form). In order to save online capacity and to keep the transmission stable, we kindly ask you to turn off your camera and microphone immediately after joining the session and during the lecture.
Discussion via Chat Room
The discussion will be held via the Chat Room function of GoToMeeting. If you would like to join the discussion, please type in your question into the chat area and moderators will pose the question to the speaker or arrange a dialogue if applicable.
The BIH Lecture will be recorded for the documentation on our website. If you do not wish to be recorded, please make sure your camera and microphone are turned off at any time.